Last Updated : May 17, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
evolocumab (Repatha)
Therapeutic Area: Primary hyperlipidemia
Draft recommendations posted for stakeholder feedback: May 16, 2024
End of feedback period: May 31, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
Retinal vein occlusion
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Generalized Myasthenia Gravis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Chronic lymphocytic leukemia (CLL).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic urothelial cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Iron deficiency in adult patients with heart failure
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic colorectal cancer (mCRC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Relapsed or refractory large B-cell lymphoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : May 17, 2024